GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CARISMA Therapeutics Inc (FRA:W2J) » Definitions » Inventories, Raw Materials & Components

CARISMA Therapeutics (FRA:W2J) Inventories, Raw Materials & Components : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is CARISMA Therapeutics Inventories, Raw Materials & Components?

CARISMA Therapeutics's inventories, raw materials & components for the quarter that ended in Dec. 2024 was €0.00 Mil.


CARISMA Therapeutics Inventories, Raw Materials & Components Historical Data

The historical data trend for CARISMA Therapeutics's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CARISMA Therapeutics Inventories, Raw Materials & Components Chart

CARISMA Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Raw Materials & Components
- - - - -

CARISMA Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CARISMA Therapeutics Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


CARISMA Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
3675 Market Street, Suite 200, Philadelphia, PA, USA, 19104
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

CARISMA Therapeutics Headlines

No Headlines